Effect of Vupanorsen on Non–High-Density Lipoprotein Cholesterol Levels in Statin-Treated Patients With Elevated Cholesterol: TRANSLATE-TIMI 70

Apolipoprotein B and Non-HDL Cholesterol Better Reflect Residual Risk Than LDL Cholesterol in Statin-Treated Patients

(2021) Camilla Ditlev Lindhardt Johannesen et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Circulating angiopoietin-like proteins in metabolic-associated fatty liver disease: a systematic review and meta-analysis

(2021) Yani Ke et al.   Lipids in Health and Disease

Apolipoprotein C-III reduction in subjects with moderate hypertriglyceridaemia and at high cardiovascular risk

(2021) Jean-Claude Tardif et al.   EUROPEAN HEART JOURNAL

Vupanorsen, an N-acetyl galactosamine-conjugated antisense drug to ANGPTL3 mRNA, lowers triglycerides and atherogenic lipoproteins in patients with diabetes, hepatic steatosis, and hypertriglyceridaemia

(2020) Daniel Gaudet et al.   EUROPEAN HEART JOURNAL

Evinacumab for Homozygous Familial Hypercholesterolemia

(2020) Frederick J. Raal et al.   NEW ENGLAND JOURNAL OF MEDICINE

Evinacumab in Patients with Refractory Hypercholesterolemia

(2020) Robert S. Rosenson et al.   NEW ENGLAND JOURNAL OF MEDICINE

Lipid-Lowering Agents

(2019) Robert A. Hegele et al.   CIRCULATION RESEARCH

N-acetyl galactosamine-conjugated antisense drug to APOC3 mRNA, triglycerides and atherogenic lipoprotein levels

(2019) Veronica J Alexander et al.   EUROPEAN HEART JOURNAL

Effects of free omega-3 carboxylic acids and fenofibrate on liver fat content in patients with hypertriglyceridemia and non-alcoholic fatty liver disease: A double-blind, randomized, placebo-controlled study

(2018) Jan Oscarsson et al.   Journal of Clinical Lipidology

Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome

(2018) Gregory G. Schwartz et al.   NEW ENGLAND JOURNAL OF MEDICINE

Integrated Assessment of the Clinical Performance of GalNAc3-Conjugated 2′-O-Methoxyethyl Chimeric Antisense Oligonucleotides: I. Human Volunteer Experience

(2018) Stanley T. Crooke et al.   Nucleic Acid Therapeutics

ANGPTL3 Deficiency and Protection Against Coronary Artery Disease

(2017) Nathan O. Stitziel et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease

(2017) Marc S. Sabatine et al.   NEW ENGLAND JOURNAL OF MEDICINE

Cardiovascular and Metabolic Effects of ANGPTL3 Antisense Oligonucleotides

(2017) Mark J. Graham et al.   NEW ENGLAND JOURNAL OF MEDICINE

Genetic and Pharmacologic Inactivation of ANGPTL3 and Cardiovascular Disease

(2017) Frederick E. Dewey et al.   NEW ENGLAND JOURNAL OF MEDICINE

The Effects of 2′-O-Methoxyethyl Containing Antisense Oligonucleotides on Platelets in Human Clinical Trials

(2017) Stanley T. Crooke et al.   Nucleic Acid Therapeutics

Injection site reactions after subcutaneous oligonucleotide therapy

(2016) Leonie van Meer et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes

(2015) Christopher P. Cannon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Mutations in theANGPTL3Gene and Familial Combined Hypolipidemia: A Clinical and Biochemical Characterization

(2012) Ilenia Minicocci et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Exome Sequencing,ANGPTL3Mutations, and Familial Combined Hypolipidemia

(2010) Kiran Musunuru et al.   NEW ENGLAND JOURNAL OF MEDICINE